# ASX ANNOUNCEMENT MARKET RELEASE

22 February 2023

# Artrya Strengthens Board with new Director

Key Points:

- Ms Kate Hill appointed to the Artrya Board as an independent non-executive director
- Ms Hill, based in Sydney Australia, is an experienced director of ASX-listed companies
- She has board level experience at technology companies and in the biotech and medical devices sector
- Executive Director John Konstantopoulos resigns from Board

Perth, Western Australia., (22 February 2023) – Australian medical technology company, Artrya Limited (ASX: AYA) (Artrya or the Company) is announcing the appointment of Ms Kate Hill to the Artrya Limited Board as an independent non-executive director.

Artrya Chair, Bernie Ridgeway, said he is delighted to welcome Ms Hill to the Board and looks forward to working with her to advance Artrya's growth strategy as an AI medical technology company.

"Kate's experience at board level with ASX listed companies, particularly in the technology, biotech and medical devices sectors will be invaluable as Artrya moves into its next phase of growth," Mr Ridgeway said.

Ms Hill, who is based in Sydney, said she is looking forward to contributing to Artrya's strategic evolution.

"The cutting-edge work that Artrya is doing makes the prospect of being on the Board very exciting. Using Al to help save lives is exactly where this sort of technology should be deployed. I also know there are some important value inflexion opportunities over the next year or two, and I intend to be very focused on building shareholder value," Ms Hill said.

Co-founder and Executive Director John Konstantopoulos resigns from the Artrya Board and remains with the Company. The Artrya Board thanks John for his significant contribution over the past four years in co-founding and progressing the Company to this point in its development.

## About Ms Hill

Ms Hill is an experienced non-executive director of ASX listed companies and has particular expertise at board level in both technology companies and also the biotech and medical devices sectors. In addition, she has experience of other listing exchanges including Nasdaq (US) and AIM (UK).

#### Artrya Limited

ACN 624 005 741 1257 Hay Street, West Perth WA 6005 PO Box 567, West Perth WA 6872 www.artrya.com T: +618 6478 7816 Kate previously spent over 20 years as an audit partner at Deloitte, serving both ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment.

She is currently the non-executive Chair of Seeing Machines Limited (LON:SEE) and a Director and Chair of the Audit and Risk Committee of Countplus Limited (ASX:CUP). She has been a non-executive Director and Chair of the Audit and Risk Committee of Elmo Software (ASX:ELO).

She is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors. She holds a BSc (Hons) in Mathematics and Statistics from the University of Bristol, UK.

This announcement was approved by the Artrya Board.

For further information please contact:

John Barrington Artrya Limited +61 419 850 502 investors@artrya.com

### About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information: www.artrya.com